We have updated our terms and conditions and privacy policy
Click “Continue” to accept and continue with ET HealthWorld
Dear user,
ET HealthWorld privacy and cookie policy has been updated to align with the new data regulations in European Union. Please review and accept these changes below to continue using the website.
You can see our privacy policy & our cookie policy. We use cookies to ensure the best experience for you on our website.
If you choose to ignore this message, we’ll assume that you are happy to receive all cookies on ET HealthWorld.
Four COVID vaccines for children currently in trial phase: Govt tells Rajya Sabha
Omicron likely to trigger third wave, alert experts
Rebooting Cancer Awareness
The unsung hero in faster holistic recovery
Technological Disruption in Indian Health & Pharma
Do you think you are up for the challenge?
Holistic Solutions For A Healthier India
17 July
Adopting-Dynamic-Technologies
In a written reply to the Lok Sabha, Karad said the GST levied on health insurance premium is 18 per cent.
Recommended by Colombia
125000+ Industry Leaders read it everyday
Eris Lifesciences today announced its entry into India’s INR 35-40 bn Insulin and GLP1 agonists market through Eris MJ Biopharm Ltd., a special purpose Joint Venture between Eris and Mumbai based MJ Biopharm Pvt Ltd.
The World Health Organization (WHO) identified on Friday the new South African strain as one of concern, as it is reported to carry a high number of mutations – 32 -which possibly makes it more transmissible and dangerous.
We have various options to advertise with us including Events, Advertorials, Banners, Mailers, Webinars etc.
Please contact us to know more details.
Get ETHealthworld‘s top stories every morning in your email inbox.
125000+ Industry Leaders read it everyday
Follow @ETHealthworld for the latest news, insider access to events and more.
